Latest news with #2024UniversalRegistrationDocument
Business Upturn
3 days ago
- Business
- Business Upturn
Atos Group publishes estimated 2025 half-year liquidity position reflecting limited cash consumption in the half
By GlobeNewswire Published on July 20, 2025, 23:00 IST Press Release Atos Group publishes estimated 2025 half-year liquidity position reflecting limited cash consumption in the half Paris, July 20th, 2025 – Atos Group (Euronext Paris: ATO) today publishes an estimated 2025 half-year liquidity position. This publication is part of the regular reporting requirements defined and agreed with the Group's financial creditors. Net change in cash1 in the first half of 2025 is estimated at c. €-96 million (vs €-686 million in the first half of 2024), without any usage of account receivable factoring or specific optimization on trade payables. This is before the estimated impact of exchange rate fluctuation of €-103 million (mainly driven by the EUR/USD evolution during the half) and excluding the €-175 million variance in payments received in advance of invoice payment due date. As at June 30, 2025, Atos Group liquidity2 is estimated at €1,804 million, compared to €2,179 million as of December 31, 2024 and more than €1.1 billion above the minimum €650 million level required by credit documentation. It was comprised of: In € million June 30, 2025 (estimated) Dec 31, 2024 (actuals) Variation Cash & cash equivalent 1,364 1,739 (374) Of which payments received in advance of invoice payment due date 143 319 (175) Undrawn revolving credit facility 440 440 – Total liquidity2 1,804 2,179 (374) The liquidity report is available on the company website ( Disclaimer This document contains forward-looking statements that involve risks and uncertainties, including references, concerning the Group's expected growth and profitability in the future which may significantly impact the expected performance indicated in the forward-looking statements. These risks and uncertainties are linked to factors out of the control of the Company and not precisely estimated, such as market conditions or competitors' behaviors. Any forward-looking statements made in this document are statements about Atos's beliefs and expectations and should be evaluated as such. Forward-looking statements include statements that may relate to Atos's plans, objectives, strategies, goals, future events, future revenues or synergies, or performance, and other information that is not historical information. Actual events or results may differ from those described in this document due to a number of risks and uncertainties that are described within the 2024 Universal Registration Document filed with the Autorité des Marchés Financiers (AMF) on April 10, 2025 under the registration number D.25-0238. Atos does not undertake, and specifically disclaims, any obligation or responsibility to update or amend any of the information above except as otherwise required by law. This document does not contain or constitute an offer of Atos's shares for sale or an invitation or inducement to invest in Atos's shares in France, the United States of America or any other jurisdiction. This document includes information on specific transactions that shall be considered as projects only. In particular, any decision relating to the information or projects mentioned in this document and their terms and conditions will only be made after the ongoing in-depth analysis considering tax, legal, operational, finance, HR and all other relevant aspects have been completed and will be subject to general market conditions and other customary conditions, including governance bodies and shareholders' approval as well as appropriate processes with the relevant employee representative bodies in accordance with applicable laws. About Atos Group Atos Group is a global leader in digital transformation with c. 72,000 employees and annual revenue of c. €10 billion, operating in 68 countries under two brands — Atos for services and Eviden for products. European number one in cybersecurity, cloud and high-performance computing, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos is a SE (Societas Europaea) and listed on Euronext Paris. The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space. Contact Investor relations: [email protected] Individual shareholders: +33 8 05 65 00 75 Media relations: [email protected] 1 Net change in cash is defined as the variance in cash and cash-equivalent – before impact of exchange rate fluctuation – excluding (i) the variance of the drawn portion of the RCF and (ii) the variance in working capital optimization actions (which include cash in advance received from customers, account receivable factoring and specific optimization of trade payables) 2 Liquidity is defined as the sum of (i) the consolidated cash and cash-equivalent position of the Group and (ii) the amounts available under any undrawn committed facilities (including committed overdrafts). Consolidated cash and cash-equivalent includes trapped cash and unpooled cash and excludes cash held in escrow accounts in order to provide cash collateral. Attachment 20250720 – PR – Atos Group – June 2025 liquidity Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Wire
11-07-2025
- Business
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of June 30 th, 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French 'Code de Commerce' and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or 'AMF'), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of June 30 th, 2025. * 192,300 free shares have been issued during the month in accordance with the plans detailed in section 5.1.5.2 of the 2024 Universal Registration Document, released on April 29, 2025. (1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. (2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Business Wire
07-07-2025
- Business
- Business Wire
Sopra Steria: Weekly Disclosure of Transactions in Own Shares From June 30 th to July 4 th, 2025
PARIS--(BUSINESS WIRE)--Regulatory News: Pursuant to implementing Directive of Commission Regulation (EC) No. 596/2014 of 16 April 2014 on the abuses of market and in accordance with Article 241-4 of the AMF General Regulation, Sopra Steria Group (Paris:SOP) hereby discloses the transactions in its own shares carried out on 1 st July 2025: Trading day Type of transaction Number of shares Weighted average price (EUR) Total amount (EUR) 01/07/2025 Transfer 143,164 N/A N/A Expand Transfer outside a trading venue carried out under the delivery and final allotment, to the beneficiaries who meet all the conditions of the plan after application of the performance conditions, of the free performance shares of the plan LTI 2022 authorised by Sopra Steria's General Meeting of 26/05/2021 and decided on 1 st June 2022. Delivery date in accordance with the terms and conditions of the Plan (see pages 285-286 of the 2024 Universal Registration Document). Disclaimer This document is a free translation into English of the original French press release. It is not a binding document. In the event of a conflict in interpretation, reference should be made to the French version, which is the authentic text.
Business Wire
03-07-2025
- Business
- Business Wire
GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement
PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the " Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 3,908,715.39 private placement (the ' Private Placement '). The Private Placement resulted in the issuance of 21,251,267 ordinary shares of the Company (the " Offered Shares"). The Offered Shares will be admitted to trading on Euronext Paris on July 3, 2025 (ISIN FR0013183985/SIGHT). The issuance of: The 1,850,000 pre-funded warrants (the " Offered Pre-Funded Warrants") giving the right to subscribe to 1,850,000 additional ordinary shares (the " Pre-Funded Warrant Shares"); and The 23,101,267 warrants (the " Offered Investor Warrants") giving the right to subscribe to 23,101,267 additional ordinary shares (the " Investor Warrant Shares") is expected to take place tomorrow, July 4, 2025. The Offered Investor Warrants will be admitted to trading on the Euronext Growth market in Paris (" Euronext Growth Paris") on July 7, 2025 (ISIN FR0014010IB4/SIGBS). The Offered Pre-Funded Warrants will not be admitted to trading on any venue. Part of the proceeds, EUR 0.7 million, has been used for the repayment in principal on the convertible bonds held by Heights Capital through offset against their subscription. Maxim Group, LLC acted as sole placement agent for the Private Placement in the United States, pursuant to an agreement entered into with the Company. Risk factors The Company draws the attention of the public to the risk factors relating to the Company and its business described in its 2024 Universal Registration Document, as amended by the Information Document published by the Company on July 1 st, 2025, both of which are available free of charge on the Company's website ( . About GenSight Biologics S.A. GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Disclaimer Not for release, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South Africa. This press release and the information contained herein do not contain or constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for securities in the United States of America or in any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act, or under the securities laws of any state or other jurisdiction of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or any other jurisdiction of the United States. GenSight does not intend to make a public offering of the securities in the United States of America. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. Forward-Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds of the Private Placement; the anticipated cash runway of the Company; and future expectations, plans and prospects of the Company. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' and 'future' or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed Private Placement and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the filings the Company makes with the AMF from time to time. The Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Yahoo
04-06-2025
- Business
- Yahoo
Renewal of the drawdown under the Revolving Credit Facility for a six-month period
Press release 4 June 2025Renewal of the drawdown under the Revolving Credit Facility for a six-month periodParis, 4 June 2025 - Clariane ( - ISIN FR0010386334) announces that it has renewed the drawdown of its RCF (Revolving Credit Facility) for a period of 6 months for an amount of €490.8 million, in accordance with the terms of the contract signed February 14th, addition to the usual conditions, the Group points out that the drawdown and renewal of its RCF line are subject to a minimum liquidity level of €300 million on the day of the drawdown or renewal, which includes the RCF drawn down. This document contains forward-looking statements that involve risks and uncertainties, including those included or incorporated by reference, concerning the Group's future growth and profitability that could cause actual results to differ materially from those indicated in the forward-looking statements. These risks and uncertainties relate to factors that the Company cannot control or estimate precisely, such as future market conditions. The forward-looking statements made in this document constitute expectations for the future and should be regarded as such. Actual events or results may differ from those described in this document due to a number of risks and uncertainties described in Chapter 2 of the 2024 Universal Registration Document filed with the AMF on 1 April 2025 under registration number D.25-0209, available on the Company's website ( and that of the AMF ( All forward-looking statements included in this document are valid only as of the date of this press release. Clariane S.E. undertakes no obligation and assumes no responsibility to update the information contained herein beyond the requirements of applicable are cautioned not to place undue reliance on these forward-looking statements. Neither Clariane nor any of its directors, officers, employees, agents, affiliates or advisors accepts any responsibility for the reasonableness of any assumptions or opinions expressed or for the likelihood of any projections, prospects or performance being achieved. Any liability for such information is expressly excluded. Nothing in this document is, or should be construed as a promise or representation regarding the future. Furthermore, nothing contained in this document is intended to be or should be construed as a forecast of results. Clariane's past performance should not be taken as a guide to future performance. The main Alternative Performance Indicators (APIs), such as EBITDA, EBIT, net debt and financial leverage, are defined in the Universal Registration Document available on the Company's website at ClarianeClariane is the leading European community of care in times of vulnerability. It has operations in six countries: Belgium, France, Germany, Italy, the Netherlands and Spain. Relying on their diverse expertise, each year, the Group's 60,000 professionals provide services to 900,000 patients and residents in three main areas of activity: care homes (Korian, Seniors Residencias, etc.), healthcare facilities and services (Inicea, Ita, Grupo 5, etc.), and alternative living solutions (Petits-fils, Ages & Vie, etc.). In June 2023, Clariane became a purpose-driven company and added to its bylaws a new corporate purpose, common to all its activities: 'taking care of each person's humanity in times of vulnerability'.Clariane has been listed on Euronext Paris, Section B since November 2006. The Group joined the SBF 120 index and the CAC® SBT 1.5° index on 23 September ticker: - ISIN: Bisseuil Benoît Lesieur Head of Investor Relations Deputy Head of Investor Relations – ESG +33 6 58 60 68 69 +33 6 64 80 15 90 Julie Mary Florian Bachelet Press officer Press officer +33 6 59 72 50 69 +33 6 79 86 78 23 Attachment Press Release Clariane-renewal of drawdown under the RCFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
